Update on antiparkinsonian agents.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001812:Blood-Brain Barrier; D001971:Bromocriptine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000009:adverse effects; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000037:antagonists & inhibitors; D010276:Parasympatholytics / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects
D000978:Antiparkinson Agents; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D011954:Receptors, Dopamine; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine